Clinical trials: HPV-16/ 18
Cervical Intraepithelial Neoplasia 3
Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation
This study is to follow up on the change of immune response by measuring HPV type 16/18 E6 and E7 specific T cell response and lesion condition in subjects who have administered in DNA-based therapeutic vaccine.
- Trial name
- GX-188E (NCT02411019)
- Testing
- GX-188E
- Where
- South Korea
- Volunteers
- 67 people
- Sponsor
- Genexine, Inc.
Infections, Papillomavirus
Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old
The current study evaluates the immunogenicity and safety in 4-6 years old female subjects (experimental group) receiving Cervarix according to a 2-dose schedule (Month 0, 6), as compared to 4-6 years old female subjects (control…
- Trial name
- NCT01627561
- Testing
- Cervarix, Priorix, Infanrix
- Where
- 4 sites in Colombia, Mexico and 1 more
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Anal Intraepithelial Neoplasia, High Grade Squamous Intraepithelial Neoplasia
VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions
This phase II trial studies the use of human papillomavirus (HPV) deoxyribonucleic acid (DNA) plasmids therapeutic vaccine VGX-3100 (VGX-3100) and electroporation in treating patients with human immunodeficiency virus…
- Conditions
- Anal Intraepithelial Neoplasia, High Grade Squamous Intraepithelial Neoplasia, HIV Positivity, Human Papillomavirus-16 Positive
- Trial name
- NCT03603808
- Testing
- Electroporation, HPV DNA Plasmids Therapeutic Vaccine VGX-3100, Laboratory Biomarker Analysis
- Where
- 8 sites in United States, Puerto Rico
- Volunteers
- 44 people
- Sponsor
- AIDS Malignancy Consortium
Cervical Cancer, Precancerous Condition
Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer form forming, growing, or coming back. Vaccines may help the body build an effective immune response against human papillomavirus and may be effective in…
- Trial name
- NCT00128661
- Testing
- human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine, hepatitis A inactivated virus vaccine
- Where
- Costa Rica
- Volunteers
- 7,466 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Genital Infection Viral, HUMAN PAPILLOMA VIRUS
Phase II Study of HPV Therapeutic Vaccine in HPV Infected Women With Normal Cytology or ASCUS/LSIL
Human Papillomavirus (HPV) 16 and HPV 18 (the two virus genotypes targeted by the ProCervix vaccine) are the most common HPV genotypes associated with at least 70% of squamous cell carcinomas and 82% of adenocarcinomas of the…
- Trial name
- RHEIA-VAC (NCT01957878)
- Testing
- ProCervix
- Where
- 40 sites in Belgium, Finland and 5 more
- Volunteers
- 239 people
- Sponsor
- Genticel
Infections, Papillomavirus
Human Papillomavirus (HPV) Vaccine (Cervarix TM) Efficacy, Immunogenicity & Safety Trial in Adult Japanese Women With GSK Biologicals HPV-16/18 Vaccine
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. Indeed, certain oncogenic types of HPV can infect the cervix (part of the uterus or womb).
- Trial name
- NCT00316693
- Testing
- HPV-16/18 vaccine (Cervarix™), Aimmugen™
- Where
- 4 sites in Japan
- Volunteers
- 1,046 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Papillomavirus, Papillomavirus Vaccines
Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation.
Human papillomavirus infection has clearly been recognized as the cause of cervical cancer. Indeed, the infection of the cervix by certain oncogenic types of HPV, if not cleared , can lead over time to cervical cancer in women .
- Trial name
- NCT00250276
- Testing
- Cervarix™
- Where
- 8 sites in Denmark, Lithuania and 1 more
- Volunteers
- 798 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Papillomavirus Infection
Post-marketing Surveillance of GSK Biologicals' Cervarix™ When Administered to Healthy Females in Sri Lanka
This PMS study aims to collect safety and reactogenicity data of Cervarix in the local population as per the licensing requirement of the Sri Lankan regulatory authority.
- Trial name
- NCT01551537
- Testing
- Cervarix data collection, Data Collection
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Papillomavirus Infection
Clinical Evaluation of the APTIMA® HPV 16 18/45 Genotype Assay on the PANTHER® System
The objective of the clinical study is to evaluate the AHPV-GT Assay using the PANTHER System in cervical cancer screening. This objective will be accomplished in the ASC-US Study by evaluating the performance characteristics of…
- Trial name
- NCT01694875
- Testing
- APTIMA HPV Assay
- Where
- 3 sites in United States
- Volunteers
- 2,200 people, healthy volunteers welcome
- Sponsor
- Gen-Probe, Incorporated
Cervical Cancer
Combination of Durvalumab and BVAC-C in Patients With HPV 16 or 18 Positive Cervical Cancer Failure to First-Line Platinum-based Chemotherapy
This is an exploratory, open label, multi-center trial to evaluate the safety and efficacy of combination of durvalumab with BVAC-C in patients with cervical cancer refractory to or relapse after platinum-based first-line…
- Trial name
- NCT04800978
- Testing
- BAVC-C+Durvalumab
- Volunteers
- 37 people
- Sponsor
- Samsung Medical Center
Infections, Papillomavirus
Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18
Human Papilloma virus (HPV) are viruses that cause a common infection of the skin and genitals in men and women. Several types of HPV infection are transmitted by sexual activity and, in women, can infect the cervix (part of the…
- Trial name
- NCT00122681
- Testing
- Cervarix™, Havrix™-based investigational formulation
- Where
- 138 sites in United States, Australia and 12 more
- Volunteers
- 18,729 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cervical Cancer, Genital Warts
Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)
The primary purpose of the study is to determine if GARDASIL™ (V501) is able to prevent cervical cancer.
- Trial name
- FUTURE II (NCT00092534)
- Testing
- Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine
- Volunteers
- 12,167 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HPV16/18 Positive
Investigator-Initiated Study of BBM-C101 Injection in Subjects With HPV16/18 Infection
This is a single-arm, single-center, open-label Investigator-Initiated Trial (IIT) designed to evaluate the safety and efficacy of BBM-C101 Injection in subjects with HPV16/18 infection and histopathologically confirmed ≤ Grade 2…
- Trial name
- NCT07714577
- Testing
- BBM-C101
- Volunteers
- 200 people
- Sponsor
- Tianjin First Central Hospital
Human Papillomavirus 16, Human Papillomavirus 18
Integrated Cervical Cancer Screening in Mayuge District Uganda (ASPIRE Mayuge)
The purpose of this pragmatic cluster randomized control trial is to test the effectiveness of cervical cancer screening follow-up completion using two implementation approaches for self-collected HPV testing in a rural…
- Conditions
- Human Papillomavirus 16, Human Papillomavirus 18, Papillomavirus Infections, Cervical Cancer
- Trial name
- ASPIRE (NCT04000503)
- Testing
- Self-collected HPV testing for cervical cancer screening
- Where
- Uganda
- Volunteers
- 2,019 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18
A Phase III Study of Human Papillomavirus (HPV)-16/18 Vaccine.
A Phase III Double Blinded, Randomized Controlled Study to Evaluate Efficacy of Protection Against HPV-16 and 18 Related Diseases, Immunogenicity and Safety of Recombinant Human Papillomavirus Virus-like Particle Vaccine (Type 16…
- Conditions
- Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18, Cervical Intraepithelial Neoplasia
- Trial name
- NCT02733068
- Testing
- HPV-16/18 vaccine
- Volunteers
- 12,000 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
Human Papillomavirus
Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 Vaccine in Healthy Females
Evaluate immunogenicity and safety of recombinant human papillomavirus bivalent ( types 16 and 18 ) vaccine ( Yeast )in different age group. And evaluate persistence of immune response in 9-17years age group.
- Trial name
- NCT02740790
- Testing
- HPV vaccine
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
Cervical Intraepithelial Neoplasia 3
Safety and Efficacy of GX-188E Administered Via EP Plus GX-I7 or Imiquimod.
This is a study to investigate the safety and efficacy of GX-188E administered IM plus local administration of GX-I7 or Imiquimod at cervix in subjects with cervical intraepithelial neoplasia (CIN) 3.
- Trial name
- NCT03206138
- Testing
- GX-188E, GX-I7, GX-188E, Imiquimod
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Seoul St. Mary's Hospital